Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID-19.
Eur Arch Otorhinolaryngol
; 279(12): 5951-5953, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2304182
ABSTRACT
INTRODUCTION:
Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD), lasting more than 6 months. Recently, platelet-rich plasma (PRP) was used in patients with non-COVID-19 COD and authors reported encouraging results.METHODS:
In the present study, we investigated the usefulness and safety of PRP injection in 56 patients with COVID-19 COD by the Sniffing Stick test (TDI score) and a linker-scale from 0 (none) to 3 (strong) and we compare the result to a control group.RESULTS:
At 1 month post-PRP injection, the mean TDI scores significantly improved by 6.7 points in the PRP group (p < 0,001), the mean self-assessment of improvement in smell function was 1.8 (mild-to-moderate) in the PRP group, which was significantly higher than the score (0.3) in the control group (p < 0,001).CONCLUSION:
Our results showed that PRP in the olfactory cleft can increase the olfactory threshold 1 month after the injection. Moreover, our results suggest that timing of treatment may be an important factor and that PRP is a safe treatment, because no adverse effects were reported throughout the study. TRIAL REGISTRATION NUMBER NCT05226546.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Platelet-Rich Plasma
/
COVID-19
/
Olfaction Disorders
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Eur Arch Otorhinolaryngol
Journal subject:
Otolaryngology
Year:
2022
Document Type:
Article
Affiliation country:
S00405-022-07560-y
Similar
MEDLINE
...
LILACS
LIS